NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NeoImmuneTech
NeoImmuneTech
National Institutes of Health Clinical Center (CC)
Numab Therapeutics AG
Intensity Therapeutics, Inc.
Nektar Therapeutics
University of California, San Francisco